每经AI快讯，立方制药12月30日晚间发布公告称，公司第六届第三次董事会会议于2025年12月30日在 公司会议室以现场结合通讯表决方式召开。会议审议了《关于签署〈药品上市许可持有人转让合同〉的 议案》等文件。 （记者 王晓波） 每经头条（nbdtoutiao）——2025十大财经新闻出炉！护航、酣战、变局、狂飙分别指向哪些大事件？ ...

证券代码：003020 证券简称：立方制药 公告编号：2025-078 合肥立方制药股份有限公司 关于签署《药品上市许可持有人转让合同》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次交易存在药品监管部门审批环节不能获得通过的风险。 2、本次交易不构成关联交易，不构成重大资产重组。 2025 年 12 月 30 日，合肥立方制药股份有限公司（以下称"公司"或"立 方制药"）召开第六届董事会第三次会议，审议通过了《关于签署〈药品上市许 可持有人转让合同〉的议案》。同日，公司与葵花药业集团佳木斯鹿灵制药有限 公司（以下称"鹿灵葵花"）签订了《美沙拉秦肠溶片 MAH 转让合同》，决定 以人民币（下同）3,400.00 万元转让美沙拉秦肠溶片药品的所有权，现将相关情 况公告如下： 一、交易概述 1、基本情况 公司拟向鹿灵葵花转让所持有的"美沙拉秦肠溶片（规格：0.5g）"药品上 市许可持有人（以下简称"持有人"或"MAH"）及相关权益（以下简称"标 的产品"或"合同产品"）。 立方制药合法持有"美沙拉秦肠溶片（规格：0.5g）"的药品批准文 ...

证券代码：003020 证券简称：立方制药 公告编号：2025-077 合肥立方制药股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 合肥立方制药股份有限公司（以下简称"公司"）第六届董事会第三次会议 于 2025 年 12 月 26 日以电子邮件、电话、短信等方式通知公司全体董事。会议 于 2025 年 12 月 30 日在公司会议室以现场结合通讯表决方式召开，会议应出席 董事 8 人，实际出席董事 8 人，其中董事邓晓娟女士、独立董事杨模荣先生以通 讯方式参会并表决。公司高级管理人员列席了会议。会议由公司董事长季俊虬先 生主持。 本次董事会会议的召集、召开程序符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定。 二、董事会会议审议情况 与会董事经过认真审议并投票表决，审议通过了如下议案： 1、《关于签署〈药品上市许可持有人转让合同〉的议案》 同意公司以 3,400 万元（含税）的价格向葵花药业集团佳木斯鹿灵制药有限 公司转让公司持有的美沙拉秦肠溶片（规格：0.5g）药品上市 ...

Group 1 - The company has signed a contract with Kew Flower Pharmaceutical Group Jiamusi Luling Pharmaceutical Co., Ltd. for the transfer of ownership of Mesalazine Enteric-Coated Tablets [1] - The transfer price for the ownership of the drug is set at 34 million yuan [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Luling Kewhua, has acquired the marketing authorization and related production technology for Mesalazine enteric-coated tablets (0.5g specification) from Lifan Pharmaceutical for 34 million yuan (including tax) [1] Group 1: Transaction Details - The acquisition involves a change of the marketing authorization holder, which requires approval from the National Medical Products Administration [1] - The transaction does not constitute a related party transaction or a major asset restructuring [1] - The payment for the contract is divided into three installments, and the contract is valid until the marketing authorization holder is changed to Luling Kewhua and the production site is changed or increased to a designated site, completing verification of three batches of production and passing inspection [1] Group 2: Strategic Implications - The transaction aims to implement the "One Elderly" strategy, enrich the product pipeline, and strengthen the company's advantage in gastrointestinal medications [1]

Group 1 - The Anhui Provincial Health Commission and other authorities have released the first batch of "new quality drug and medical device" product catalog to accelerate the promotion and application of innovative medical products, fostering new productive forces in the biopharmaceutical industry [1] - A total of 60 "new quality drug and medical device" products were announced, with 45 products from Hefei, accounting for 75% of the total in the province, highlighting Hefei's strong innovation capabilities and industrial clustering effect [1] - In the biopharmaceutical sector, all three selected biopharmaceuticals in the province are from Hefei, including innovative drugs for tuberculosis/influenza prevention by Zhifei Longcom and anti-tumor drugs by Anke Bio [1] Group 2 - Hefei's Industrial and Information Technology Bureau is actively promoting the innovative development of the biopharmaceutical industry, focusing on building a collaborative industrial ecosystem involving government, industry, academia, research, application, and finance [2] - The city is nurturing local leading enterprises such as Anke Bio, Opcon Vision, and Meiya Optoelectronics while successfully attracting innovative companies like Ruisi Digital Technology through high-level platforms [2] - Collaboration with institutions like the University of Science and Technology of China and Anhui University of Traditional Chinese Medicine has led to the incubation of technology-based SMEs, creating a favorable development pattern for large, medium, and small enterprises [2]

合肥立方制药股份有限公司 2025年中期权益分派实施公告 证券代码：003020 证券简称：立方制药 公告编号：2025-075 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 合肥立方制药股份有限公司（以下简称"公司"）2025 年中期权益分派方 案已获 2025 年 11 月 17 日召开的 2025 年第二次临时股东会审议通过，现将权 益分派事宜公告如下： 一、股东会审议通过利润分配方案情况 1、公司于2025年11月17日召开2025年第二次临时股东会，审议通过了《关 于2025年中期利润分配预案的议案》。公司2025年中期权益分派方案为：拟以 实施权益分派股权登记日的总股本为基数分配利润，公司拟向全体股东每10股 派发现金红利人民币2.00元（含税），以此初步计算，公司拟派发现金红利合 计人民币38,036,436.40元（含税）。本次利润分配不送红股，不以资本公积转 增股本。 2、自上述权益分派方案披露至实施期间，公司股本总额未发生变化。截至 目前，公司总股本为190,182,182股。 3、公司总股本发生变动的，按照每股分配比例不变的原则，相应调 ...

Core Viewpoint - Company received acceptance notification for drug registration applications for Dapagliflozin Metformin Extended-Release Tablets (I, II, III) from the National Medical Products Administration [1] Company Summary - Dapagliflozin Metformin Extended-Release Tablets are a fixed-dose combination formulation consisting of SGLT2 inhibitor Dapagliflozin and the biguanide drug Metformin [1] - The combination aims to provide comprehensive and effective blood glucose control for adult patients with type 2 diabetes [1] Industry Summary - The product is co-developed by Bristol-Myers Squibb Company and AstraZeneca AB [1] - As of the announcement date, eight domestic companies have received approval for similar products, excluding imported ones [1]

Core Viewpoint - The company, Lianfang Pharmaceutical, has received a notice of acceptance for the drug registration application of Dapagliflozin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating progress in bringing this combination diabetes medication to market [1] Group 1: Product Details - Dapagliflozin Metformin Extended-Release Tablets are a fixed-dose combination formulation that includes Dapagliflozin, an SGLT2 inhibitor, and Metformin, a biguanide, which work synergistically to control blood sugar levels [1] - Dapagliflozin lowers blood sugar by promoting urinary glucose excretion, while Metformin primarily reduces hepatic glucose output and improves insulin sensitivity [1] - This combination aims to provide more comprehensive and effective blood sugar control for adult patients with type 2 diabetes [1] Group 2: Market Context - The product is co-developed by Bristol-Myers Squibb Company and AstraZeneca AB, indicating a collaboration between major pharmaceutical companies [1] - As of the date of the announcement, eight other companies have received approval for similar products in the domestic market, highlighting competitive dynamics in the diabetes medication sector [1]

Core Viewpoint - The company, Lifan Pharmaceutical, has received the acceptance notice for the drug registration application of Dapagliflozin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating progress in bringing this combination diabetes medication to market [1] Group 1: Product Details - Dapagliflozin Metformin Extended-Release Tablets are a fixed-dose combination formulation that includes the SGLT2 inhibitor Dapagliflozin and the biguanide Metformin, which work synergistically to control blood sugar levels [1] - Dapagliflozin lowers blood sugar by promoting urinary glucose excretion, while Metformin primarily reduces hepatic glucose output and improves insulin sensitivity [1] - This combination aims to provide more comprehensive and effective blood sugar control for adult patients with type 2 diabetes [1] Group 2: Market Context - The product is co-developed by Bristol-Myers Squibb and AstraZeneca, highlighting collaboration between major pharmaceutical companies in the diabetes treatment space [1] - As of the announcement date, there are eight domestic companies that have received approval for similar products, indicating a competitive market landscape for diabetes medications in China [1]